Journal article
A Randomized Dose-Ranging Study of Neuropeptide Y in Patients with Posttraumatic Stress Disorder
Sehrish Sayed, Nicholas T Van Dam, Sarah R Horn, Marin M Kautz, Michael Parides, Sara Costi, Katherine A Collins, Brian Iacoviello, Dan V Iosifescu, Aleksander A Mathe, Steven M Southwick, Adriana Feder, Dennis S Charney, James W Murrough
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | OXFORD UNIV PRESS | Published : 2018
DOI: 10.1093/ijnp/pyx109
Abstract
BACKGROUND: Anxiety and trauma-related disorders are among the most prevalent and disabling medical conditions in the United States, and posttraumatic stress disorder in particular exacts a tremendous public health toll. We examined the tolerability and anxiolytic efficacy of neuropeptide Y administered via an intranasal route in patients with posttraumatic stress disorder. METHODS: Twenty-six individuals were randomized in a cross-over, single ascending dose study into 1 of 5 cohorts: 1.4 mg (n=3), 2.8 mg (n=6), 4.6 mg (n=5), 6.8 mg (n=6), and 9.6 mg (n=6). Each individual was dosed with neuropeptide Y or placebo on separate treatment days 1 week apart in random order under double-blind con..
View full abstractGrants
Funding Acknowledgements
This work was supported by the Icahn School of Medicine at Mount Sinai, with additional support provided by the National Center for PTSD and the VA CT Healthcare System.